Nicox and Kowa Sign Agreement for Exclusive Rights to Glaucoma Treatment NCX 470

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories

Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 million Tiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa will…

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.

New agreement to authorize Kowa Company to develop, manufacture Nicox's NCX 470 in US

Nicox’s nitric oxide (NO)-donating bimatoprost eye drop works to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Nicox, Kowa make a deal for glaucoma drug; French techbio raises €15M

Plus, news about Clearside Biomedical: Nicox, Kowa ink licensing deal worth up to €191.5M: Kowa is gaining the exclusive rights to an experimental glaucoma treatment called NCX 470 in the US ...

Nicox and Kowa Sign Agreement for Exclusive Rights to Glaucoma Treatment NCX 470 in US and All Unlicensed Territories

Kowa has gained exclusive rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension in the US and all other territories of the world excluding Japan, China, Korea and Southeast Asia.   Kowa already has a license to NCX 470 for Japan, where it is preparing to enter a phase 3 clinical trial. NCX 470 is also licensed to Ocumension The…